Bordignon C, Yu S F, Smith C A, Hantzopoulos P, Ungers G E, Keever C A, O'Reilly R J, Gilboa E
Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
Proc Natl Acad Sci U S A. 1989 Sep;86(17):6748-52. doi: 10.1073/pnas.86.17.6748.
Two recombinant retroviral vectors encoding the cDNA of the human adenosine deaminase (ADA; EC 3.5.4.4) gene and the bacterial neomycin resistance (Neo) gene have been used to transduce bone marrow cells obtained from four patients affected by the ADA-deficient variant of severe combined immunodeficiency. By utilizing the long-term marrow culture system, freshly isolated bone marrow cells were subjected to multiple infection cycles with cell-free supernatants containing high titers of viral vector and then maintained in long-term marrow culture in the absence of any overt selection pressure. By using this experimental protocol, about 30-40% of the hematopoietic progenitors were productively transduced with the viral vector, as judged by the appearance of G418-resistant colonies derived from granulocyte/macrophage and multipotent hematopoietic progenitor cells. The vector-encoded human ADA gene was expressed efficiently in both the myeloid and lymphoid progeny of the cultured bone marrow cells, reaching levels between 15% and 100% as compared to the levels of ADA in normal bone marrow cells. The efficiency of gene transfer and ADA production was proportional to the number of infection cycles. Furthermore, transduction of the ADA vectors into the bone marrow cells derived from an ADA-deficient patient restored the capacity of the cells to respond to phytohemagglutinin and interleukin 2.
两种重组逆转录病毒载体,一种编码人腺苷脱氨酶(ADA;EC 3.5.4.4)基因的cDNA,另一种编码细菌新霉素抗性(Neo)基因,已被用于转导从四名患有严重联合免疫缺陷的ADA缺陷变体患者获得的骨髓细胞。通过利用长期骨髓培养系统,将新鲜分离的骨髓细胞用含有高滴度病毒载体的无细胞上清液进行多次感染循环,然后在没有任何明显选择压力的情况下维持长期骨髓培养。通过使用该实验方案,根据源自粒细胞/巨噬细胞和多能造血祖细胞的G418抗性集落的出现判断,约30-40%的造血祖细胞被病毒载体有效转导。载体编码的人ADA基因在培养的骨髓细胞的髓系和淋巴系后代中均有效表达,与正常骨髓细胞中ADA的水平相比,达到15%至100%的水平。基因转移和ADA产生的效率与感染循环的次数成正比。此外,将ADA载体转导到来自一名ADA缺陷患者的骨髓细胞中恢复了细胞对植物血凝素和白细胞介素2作出反应的能力。